Related Experiment Videos
Combination chemotherapy in rheumatoid arthritis
1Florance and Cope Chair of Rheumatology, University of Sydney, Royal North Shore Hospital, St Leonards, NSW, Australia.
Annals of the Rheumatic Diseases
|July 1, 1991
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
The management of rheumatoid arthritis.
The Australian journal of physiotherapy·2014
The clinical significance of indomethacin-probenecid interaction.
British journal of clinical pharmacology·2012
The effect of frusemide on indomethacin plasma levels.
British journal of clinical pharmacology·2012
Over the counter (OTC) oral remedies for arthritis and rheumatism: how effective are they?
Inflammopharmacology·2008
Costs and outcomes of total hip and knee joint replacement for rheumatoid arthritis.
Clinical rheumatology·2008
Shared genetic architecture and therapeutic targets across paediatric immune-mediated diseases.
Annals of the rheumatic diseases·2026
EXTL3 dysfunction identified as a driver of aberrant bone development in severe familial ankylosing spondylitis.
Annals of the rheumatic diseases·2026
Effects of air pollution on disease activity in patients with rheumatoid arthritis.
Annals of the rheumatic diseases·2026
Comparative safety of PICC-ports and chest ports in oncology: A monocentric retrospective cohort study.
The journal of vascular access·2026
Combinatorial effects of curcumin, morin, and phyllanthin in MDA-MB-231 and MCF-7 breast cancer cell lines.
Indian journal of pharmacology·2026
Local Therapy for Isolated Residual Metastatic Melanoma and Renal Cell Carcinoma Following Immune Checkpoint Inhibition Leading to Long-Term Remission.
Journal of immunotherapy (Hagerstown, Md. : 1997)·2026
Cost-effectiveness analysis of liposomal Irinotecan in combination with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas in Greece.
Expert review of pharmacoeconomics & outcomes research·2026